Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis

Learn more about:
Related Clinical Trial
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis

Official Title

Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis

Brief Summary

      Wilson's disease is an autosomal recessive genetically inherited disorder of copper
      metabolism, causing neurological, psychiatric and liver disease. The ATP7B gene on the 13th
      chromosome is responsible for the disease. Liver has a critical role on copper metabolism. It
      is the main site of copper accumulation and bile secretion is the only physiologic way of
      copper elimination. Due to defective production of ceruloplasmin which carries copper, wide
      amount of free copper precipitates throughout the body but particularly in the liver, eyes
      and brain. Patients are bound to lifelong chelating agents such as penicillamine, trientine
      and tetramine dihydrochloride. Unfortunately, these medications may cause severe side-effects
      such as hypersensitivity reactions, bone marrow suppression, auto-immune disease and
      sideroblastic anemia. Medical treatment of liver cirrhosis, the last stage of the illness
      that leads to morbidity and mortality in the Wilson Disease, is difficult. Liver
      transplantation is still the most effective treatment for the patients with liver cirrhosis
      in Wilson Disease. However, serious problems are accompanied with liver transplantation. Lack
      of liver donors, complications during and after the surgery, graft rejection and high costs
      are the main problems.

      There are cells in the human body that are capable to renew themselves and differentiate to a
      diverse range of specialized cell types. These are called "stem cells". Stem cells can be
      differentiated to specialized cells in appropriate medias in the laboratory. Recently, the
      differentiation potential of mesenchymal stem cells into hepatocytes is proved by
      demonstrating hepatocytes containing Y chromosome in the female who has had bone marrow
      transplantation from male donors. In many laboratory studies, it is observed that human bone
      marrow derived mesenchymal stem cells, transplanted to animals with induced liver damage,
      differentiate into the albumin producing hepatocytes without fusion. By these studies, it is
      understood that mesenchymal stem cells are more potent than other bone marrow elements in
      context of differentiation to hepatocytes. Even though the number of studies on human for the
      same purpose is few, findings are supporting those of animal experiments. Mesenchymal stem
      cells are non-immunogenic. Safety and feasibility of allogeneic transplantations between
      individuals without need of immunosuppressive drug regimen are proven. Proofs of correcting
      metabolic defects by this way are also presented in some publications. For the reasons
      mentioned above, allogeneic mesenchymal stem cell transplantation is a promising treatment
      modality especially for the hereditary metabolic diseases. By this way, non-immunogeneic
      mesenchymal stem cells which have healthy genetic structure, can manufacture the required
      enzyme, will be repopulated in the damaged tissue and contribute to the clinical improvement.

      In this study, mesenchymal stem cells will be derived from healthy volunteer donor's bone
      marrow and be expanded in-vitro, and then 1 million cells per kg will be infused to patients
      with liver cirrhosis related to Wilson disease, 50 million cells via hepatic artery and the
      remaining cells via peripheral vein. It is aimed to enable liver regeneration, decrease
      fibrosis rate, improve patient's health conditions, increase ceruloplasmin synthesis,
      ameliorate disorder of copper metabolism, decrease the need for chelating agents, increase
      living standards of patients, and prolong waiting time for liver transplantation. Finally it
      is aimed to establish a new and regenerative treatment protocol alternative to liver
      transplantation. For observation of clinical and laboratory improvement, patients are planned
      to be monitored by histopathologic examination of liver biopsies before and at 6th month
      after the treatment, monthly biochemical and hematologic blood tests and periodic radiologic
      examinations. This is a hopeful, avant garde and sophisticated study which may constitute new
      horizons in context of cellular therapies.
    



Study Type

Interventional


Primary Outcome

differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies


Condition

Wilson's Disease

Intervention

allogeneic mesenchymal stem cell transplantation


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Genetic

Estimated Enrollment

10

Start Date

April 2011

Completion Date

December 2014

Primary Completion Date

March 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Clinical, radiologic and pathologically proven Wilson's Disease with hepatic
             presentation

          -  Patients with no hepatic malignancies

          -  No co-existing serious respiratory and/or cardiovascular morbidities

          -  Patients who approved to join the study group with informed and written consent

          -  Patients with platelet count more than 30.000/mm3

        Exclusion Criteria:

          -  Clinical diagnosis of Wilson's Disease with neuropsychiatric presentation

          -  Current alcohol consumption

          -  Patients who have acute or chronic viral hepatitis infection
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Turkey

Location Countries

Turkey

Administrative Informations


NCT ID

NCT01378182

Organization ID

110S153


Responsible Party

Sponsor-Investigator

Study Sponsor

Murat Kantarcioglu

Collaborators

 Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

Study Sponsor

, , 


Verification Date

December 2014